<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Abnormal increases of <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> and plasma <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels are recently emerging as nonlipidic risk factors for cerebral atherogenesis and <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Both <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> and <z:chebi fb="0" ids="17230">homocysteine</z:chebi> share many similar bioeffects in hemostasis, but their interaction is still inconsistent </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we examined the relation between the plasma <z:chebi fb="0" ids="17230">homocysteine</z:chebi> level and <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, anticardiolipin antibody, and anti-beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I antibody in patients with noncardiac <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Systemic <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> erythrematosus patients were excluded </plain></SENT>
<SENT sid="4" pm="."><plain>The results showed a higher frequency of moderate <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> in patients with an abnormal increase of <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> only </plain></SENT>
<SENT sid="5" pm="."><plain>Neither the serum <z:chebi fb="3" ids="37445">folate</z:chebi> and <z:chebi fb="1" ids="30411">cobalamin</z:chebi> levels nor <z:chebi fb="0" ids="25297">methylenetetrahydrofolate</z:chebi> reductase allele mutation contributes to this result </plain></SENT>
<SENT sid="6" pm="."><plain>Accordingly, <z:chebi fb="0" ids="17230">homocysteine</z:chebi> interacts with <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> to promote cerebral <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> and <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The role of vasculopathic or prothrombotic autoantibody generation in response to specific pathological change such as <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> warrants further investigation </plain></SENT>
</text></document>